Evofem Biosciences, INC. (EVFM) — 8-K Filings

All 8-K filings from Evofem Biosciences, INC.. Browse 30 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (30)

8-K Filing — Nov 26, 2025
Evofem Biosciences Files 8-K: Agreement Termination & Shareholder Vote — Oct 20, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on October 20, 2025, reporting the termination of a material definitive agreement and the submission of matters to a vote
Evofem Biosciences Enters Material Definitive Agreement — Oct 17, 2025 Risk: medium
Evofem Biosciences, Inc. announced on October 13, 2025, that it has entered into a material definitive agreement. The company, formerly known as Neothetics, Inc
Evofem Biosciences Files 8-K on Material Agreement — Aug 26, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on August 26, 2025, reporting a material definitive agreement entered into on August 22, 2025. The filing also covers modi
Evofem Biosciences Files 8-K: Material Agreement & Equity Sales — Jul 2, 2025 Risk: medium
Evofem Biosciences, Inc. announced on June 26, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of eq
Evofem Biosciences Enters Material Definitive Agreement — May 22, 2025 Risk: medium
Evofem Biosciences, Inc. announced on May 19, 2025, that it has entered into a material definitive agreement. The filing does not provide specific details about
Evofem Biosciences Files 8-K for Material Agreement — May 8, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on May 8, 2025, reporting an entry into a material definitive agreement and financial statements. The filing date indicate
Evofem Biosciences Reports Material Agreement — Apr 14, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on April 14, 2025, reporting a material definitive agreement entered into on April 8, 2025. The filing also includes finan
Evofem Biosciences Reports Material Agreement — Apr 3, 2025 Risk: medium
Evofem Biosciences, Inc. filed an 8-K on April 3, 2025, reporting a material definitive agreement entered into on March 28, 2025. The filing also includes finan
Evofem Biosciences Enters Material Definitive Agreement — Mar 26, 2025 Risk: medium
Evofem Biosciences, Inc. announced on March 20, 2025, that it entered into a material definitive agreement. The company, formerly known as Neothetics, Inc., is
Evofem Biosciences Faces Delisting Concerns — Jan 10, 2025 Risk: high
Evofem Biosciences, Inc. filed an 8-K on January 10, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event re
Evofem Biosciences Changes Principal Executive Offices — Dec 23, 2024 Risk: low
On December 23, 2024, Evofem Biosciences, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 7770 Regents R
Evofem Biosciences Enters Material Definitive Agreement — Nov 25, 2024 Risk: medium
Evofem Biosciences, Inc. announced on November 19, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Neothetics, Inc.,
Evofem Biosciences Enters Material Definitive Agreement — Nov 6, 2024 Risk: medium
Evofem Biosciences, Inc. announced on October 31, 2024, the entry into a Material Definitive Agreement. The company, formerly known as Neothetics, Inc., is inco
Evofem Terminates Phexxi License Deal with 03 Life Sciences — Oct 31, 2024 Risk: high
Evofem Biosciences, Inc. announced on October 27, 2024, the termination of its exclusive license agreement with 03 Life Sciences for the commercialization of Ph
Evofem Biosciences Files 8-K: Material Agreement & Equity Sales — Oct 28, 2024 Risk: medium
Evofem Biosciences, Inc. announced on October 28, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of
Evofem Biosciences Files 8-K with Material Agreements & Equity Sales — Oct 3, 2024 Risk: medium
Evofem Biosciences, Inc. announced on September 27, 2024, that it entered into a Material Definitive Agreement. The company also reported triggering events that
Evofem Biosciences Enters Material Agreement, Files 8-K — Sep 25, 2024 Risk: medium
Evofem Biosciences, Inc. announced on September 20, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales
Evofem Biosciences Enters Material Definitive Agreement — Sep 6, 2024 Risk: medium
Evofem Biosciences, Inc. announced on September 6, 2024, that it has entered into a Material Definitive Agreement. The filing does not provide specific details
Evofem Biosciences to be Delisted from Nasdaq — Aug 30, 2024 Risk: high
Evofem Biosciences, Inc. received a notice on August 28, 2024, indicating it failed to meet the continued listing standards of The Nasdaq Stock Market LLC. The
Evofem Biosciences Enters Material Definitive Agreement — Aug 20, 2024 Risk: medium
Evofem Biosciences, Inc. announced on August 16, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details on the
Evofem Biosciences Secures $10M Loan — Jul 23, 2024 Risk: medium
On July 17, 2024, Evofem Biosciences, Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an affiliate of its largest stockhol
Evofem Biosciences Files 8-K — Jul 18, 2024 Risk: low
Evofem Biosciences, Inc. filed an 8-K on July 18, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits as of July 17, 2024. The comp
Evofem Biosciences Holds Annual Meeting, Approves Key Proposals — Jun 26, 2024 Risk: low
On June 20, 2024, Evofem Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockhol
Evofem Biosciences Terminates Adare Pharma Deal, Enters New Agreement — May 2, 2024 Risk: medium
Evofem Biosciences, Inc. announced on April 26, 2024, the termination of its Material Definitive Agreement with Adare Pharma Solutions. The company also entered
Evofem Biosciences Files Current Report — Mar 28, 2024 Risk: low
Evofem Biosciences, Inc. filed an 8-K on March 28, 2024, reporting an event on March 27, 2024. The filing is a current report under Regulation FD and includes f
Evofem Biosciences Enters Material Definitive Agreement — Mar 6, 2024 Risk: medium
Evofem Biosciences, Inc. announced on February 29, 2024, that it entered into a Material Definitive Agreement. The company, previously known as Neothetics, Inc.
Evofem Biosciences Updates Principal Executive Office Address — Feb 1, 2024
Evofem Biosciences, Inc. filed an 8-K on February 1, 2024, to update its principal executive offices to 7770 Regents Road, Suite 113-618, San Diego, CA 92122. T
Evofem Biosciences Reports Undisclosed Material Agreement — Jan 31, 2024
Evofem Biosciences, Inc. filed an 8-K on January 31, 2024, to report an "Entry into a Material Definitive Agreement" that occurred on January 30, 2024. While th
Evofem Biosciences Reports Material Definitive Agreement; Details Undisclosed — Jan 11, 2024
Evofem Biosciences, Inc. filed an 8-K on January 11, 2024, reporting an "Entry into a Material Definitive Agreement" on January 8, 2024. While the filing indica

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX